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2	
	
Abstract	34	
Besides	 their	 well‐described	 use	 as	 delivery	 systems	 for	 water‐soluble	 drugs,	35	
liposomes	 have	 the	 ability	 to	 act	 as	 a	 solubilizing	 agent	 for	 drugs	 with	 low	36	
aqueous	solubility.	However,	a	key	limitation	in	exploiting	liposome	technology	37	
is	the	availability	of	scalable,	low‐cost	production	methods	for	the	preparation	of	38	
liposomes.	 Here	 we	 describe	 a	 new	 method,	 using	 microfluidics,	 to	 prepare	39	
liposomal	 solubilising	 systems	 which	 can	 incorporate	 low	 solubility	 drugs	 (in	40	
this	case	propofol).		The	setup,	based	on	a	chaotic	advection	micromixer,	showed	41	
high	drug	 loading	 (41	mol%)	of	 propofol	 as	well	 as	 the	 ability	 to	manufacture	42	
vesicles	with	at	prescribed	sizes	(between	50	to	450	nm)	 in	a	high‐throughput	43	
setting.	Our	results	demonstrate	the	ability	of	merging	liposome	manufacturing	44	
and	 drug	 encapsulation	 in	 a	 single	 process	 step,	 leading	 to	 an	 overall	 reduced	45	
process	time.	These	studies	emphasise	the	flexibility	and	ease	of	applying	lab‐on‐46	
a‐chip	microfluidics	for	the	solubilisation	of	poorly	water‐soluble	drugs.	47	
	  48	
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1 Introduction 49	
The	 delivery	 of	 drugs	 by	 liposomes	 was	 first	 described	 in	 the	 1970s	 by	50	
Gregoriadis	(Gregoriadis	and	Ryman,	1971)	and	there	is	now	a	range	of	clinically	51	
approved	 liposome‐based	 products	 that	 improve	 the	 therapeutic	 outcome	 for	52	
patients.	Whilst	liposomes	are	commonly	considered	for	the	delivery	of	aqueous	53	
soluble	drugs,	they	are	also	well	placed	to	act	as	solubilisation	agents	for	drugs	54	
with	low	aqueous	solubility.	This	is	of	considerable	interest	given	that	more	than	55	
40%	of	all	new	chemical	entities	in	discovery	have	low	solubility	and	subsequent	56	
issues	 in	 bioavailability	 (Savjani	 et	 al.,	 2012;	 Williams	 et	 al.,	 2012).	 The	57	
encapsulation	 of	 low	 solubility	 drugs	 into	 the	 bilayer	 of	 liposomes	 allows	 not	58	
only	 for	 their	 solubilisation	 in	 an	 aqueous	 media,	 but	 furthermore	 can	 offer	59	
protection	 from	 degradation	 and	 control	 over	 the	 pharmacokinetic	 drug	60	
distribution	profile	and	improved	therapeutic	efficacy.		61	
	62	
When	 solubilising	 drug	 within	 the	 liposomal	 bilayer,	 drug	 incorporation	 and	63	
release	 rates	 has	 been	 shown	 to	 depend	 on	 the	 properties	 of	 the	 drug,	 the	64	
composition	of	the	liposomes,	the	lipid	choice	and	concentration	(Ali	et	al.,	2010;	65	
Ali	et	al.,	2013;	Mohammed	et	al.,	2004).	For	example,	 the	 log	P	and	molecular	66	
weight	 are	 often	 considered	 to	 impact	 on	 bilayer	 loading,	 and	 studies	 have	67	
shown	that	molecular	weight	may	play	a	dominant	role	(Ali	et	al.,	2013).	When	68	
considering	the	design	of	liposomes,	there	are	a	range	of	parameters	that	impact	69	
on	 bilayer	 loading	 efficacy.	 	 For	 example,	 we	 have	 previously	 shown	 that	70	
increasing	 the	 bilayer	 lipophillic	 volume	 (by	 adopting	 longer	 alkyl	 chain	 lipids	71	
within	 the	 liposomes)	 increases	 the	 loading	 ability	 of	 liposomal	 systems	72	
(Mohammed	 et	 al.,	 2004;	 Ali	 et	 al.,	 2013).	 	 Similarly,	 incorporation	 of	 charged	73	
lipids	within	 the	 liposomal	 system	may	also	 impact	on	bilayer	 loading	 through	74	
electrostatic	 repulsion	 of	 drugs	 with	 like‐charged	 liposomal	 bilayers	75	
(Mohammed	 et	 al.,	 2004).	 Incorporation	 of	 cholesterol,	 whilst	 stabilising	 the	76	
liposomes	was	also	shown	to	inhibit	bilayer	drug	loading	(Ali	et	al.,	2010)	due	to	77	
the	space‐filling	action	of	cholesterol	in	the	liposomal	bilayer.	By	increasing	the	78	
orientation	order	of	the	phospholipid	hydrocarbon	chains,	cholesterol	decreases	79	
bilayer	 permeability.	 Indeed,	 the	 presence	 of	 cholesterol	 in	 liposomes	80	
solubilising	propofol	was	shown	to	shift	the	drug	release	profile	from	zero‐order	81	
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(when	 no	 cholesterol	 was	 present)	 to	 first	 order	 (when	 11	 to	 33	 mol%	 of	82	
cholesterol	was	 incorporated).	 	 This	maps	 to	 the	 idea	 that	without	 cholesterol	83	
the	bilayer	can	be	thought	of	as	more	‘porous’	in	nature	compared	with	the	more	84	
condensed	 and	 less	 permeable	 cholesterol‐containing	 liposome	bilayers	 (Ali	 et	85	
al.,	2010).			86	
	87	
However,	whilst	a	wide	range	of	studies	have	looked	at	the	effect	of	formulation	88	
parameters	on	the	application	of	liposomes	as	solubilising	agents,	more	focus	is	89	
required	 into	 making	 liposomes	 a	 cost‐effective	 solubilising	 agent.	 Recent	90	
advances	in	lab‐on‐a‐chip	based	tools	for	process	development	has	already	lead	91	
to	microfluidic‐based	methodologies	 in	 drug	 development	 (Dittrich	 and	Manz,	92	
2006;	Weigl	et	al.,	2003;	Whitesides,	2006).	Indeed,	microfluidics‐based	methods	93	
(which	exploit	controlled	mixing	of	streams	in	micro‐sized	channels)	have	been	94	
described	for	the	manufacture	of	liposomes	and	lipid	nanoparticles	(van	Swaay,	95	
2013).	Liposome	formation	by	microfluidics	primarily	depends	on	the	process	of	96	
controlled	 alterations	 in	 polarities	 throughout	 the	 mixer	 chamber,	 which	 is	97	
followed	 by	 a	 nanoprecipitation	 reaction	 and	 the	 self‐assembly	 of	 the	 lipid	98	
molecules	into	liposomes.	Generally,	two	or	more	inlet	streams	(lipids	in	solvent	99	
and	 an	 aqueous	 phase)	 are	 rapidly	 mixed	 together	 and	 flow	 profiles	 in	 the	100	
chamber	 itself	 are	of	 low	Reynolds	numbers	and	categorized	as	 laminar.	Using	101	
microfluidic	 systems	 a	 tight	 control	 of	 the	 mixing	 rates	 and	 ratio	 between	102	
aqueous	 and	 solvent	 streams	 is	 achieved,	with	 lower	 liquid	 volumes	 required,	103	
which	facilitates	process	development	by	reducing	time	and	development	costs.	104	
The	systems	are	designed	with	the	option	of	high‐throughput	manufacturing	and	105	
are	 generally	 considered	 as	 less	 harsh	 compared	 to	 conventional	 methods	 of	106	
liposome	 manufacturing	 that	 are	 based	 on	 mechanical	 disruption	 of	 large	107	
vesicles	 into	 small	 and	 unilamellar	 ones	 (Wagner	 and	 Vorauer‐Uhl,	 2011).	108	
Within	 the	 range	 of	 microfluidic	 mixing	 devices,	 we	 use	 a	 chaotic	 advection	109	
micromixer,	a	Staggered	Herringbone	Micromixer	(SHM).	The	fluid	streams	are	110	
passed	 through	 the	 series	 of	 herringbone	 structures	 that	 allow	 for	 the	111	
introduction	of	a	chaotic	flow	profile,	which	enhances	advection	and	diffusion.	A	112	
chaotic	advection	micromixer,	as	well	as	flow	focusing	methods,	were	shown	to	113	
allow	for	scalability,	associated	with	defined	vesicle	sizes	(Belliveau	et	al.,	2012;	114	
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Jahn	 et	 al.,	 2007).	 The	 method	 based	 on	 chaotic	 advection	 was	 shown	 to	115	
reproducibly	 generate	 small	 unilamellar	 liposomes	 (SUV)	with	 tight	 control	 of	116	
the	resulting	liposome	sizes	at	flow	rates	as	high	as	70	mL/min	in	a	parallelized	117	
mixer‐setup.	 We	 have	 previously	 shown	 that	 microfluidics	 can	 be	 used	 to	118	
produce	 cationic	 liposomal	 transfection	 agents	 (Kastner	 et	 al.,	 2014),	 where	119	
design	 of	 experiments	 and	 multivariate	 analysis	 revealed	 the	 ratio	 between	120	
aqueous	and	solvent	phase	having	a	strong	relevance	for	the	formation	of	size‐121	
controlled	 liposomes.	 Within	 this	 study,	 we	 have	 exploited	 microfluidics	 to	122	
develop	 a	 high‐throughput	 manufacturing	 process	 to	 prepare	 liposomes	123	
solubilising	drug	within	their	bilayer	(Figure	1).		124	
	125	
	126	
	127	
Figure	 1:	 Schematic	 depiction	 of	 the	 liposome	 formation	 process	 based	 on	 the	128	
SHM	design,	a	chaotic	advection	micromixer	 for	(A)	empty	 liposomes,	 (B)	drug	129	
loaded	liposomes	and	(C)	chamber	layout.	130	
	131	
	132	
	133	
	134	
	135	
Width	200	µm 
Height	78	µm 
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	136	
2 Materials and Methods 137	
2.1 Materials 138	
Egg	Phosphatidylcholine	(PC)	and	Cholesterol	were	obtained	from	Sigma‐Aldrich	139	
Company	 Ltd.,	 Poole,	 UK.	 Ethanol	 and	 methanol	 were	 obtained	 from	 Fisher	140	
Scientific	 UK,	 Loughborough,	 UK.	 TRIS	 Ultra	 Pure	 was	 obtained	 from	 ICN	141	
Biomedicals,	 Inc.,	 Aurora,	 Ohio.	 Propofol	 (2,6‐Bis(isopropyl)phenol)	 and	 5(6)‐142	
Carboxyfluorescein	(CF)		was	obtained	from	Sigma‐Aldrich	Company	Ltd.,	Poole,	143	
UK.	144	
	145	
2.2 Micromixer design and fabrication 146	
The	 micromixer	 was	 obtained	 from	 Precision	 NanoSystems	 Inc.,	 Vancouver,	147	
Canada.	 The	mixer	 contained	moulded	 channels	which	were	 200	 µm	 x	 79	 µm	148	
(width	 x	 height)	 with	 herringbone	 features	 of	 50	 x	 31	 µm.	 1	 mL	 disposable	149	
syringes	were	used	for	the	inlet	streams,	with	respective	fluid	connectors	to	the	150	
chip	 inlets.	 	Formulations	 using	 the	 micromixer	 were	 performed	 on	 a	151	
NanoAssemblr™	(Precision	NanoSystems	 Inc.,	Vancouver,	Canada)	 that	allowed	152	
for	 control	of	 the	 flow	rates	 (0.5	 to	6	mL/min)	and	 the	 flow	ratios	 (1:1	 to	1:5,	153	
ratio	between	solvent:aqueous)	between	the	respective	streams.	154	
2.3 Formulation of small unilamellar vesicles using microfluidics 155	
Lipids	 (16:4	 molar	 ratio	 of	 PC	 and	 Cholesterol,	 8:1	 w/w)	 were	 dissolved	 in	156	
ethanol.	SUV	were	manufactured	by	injecting	the	lipids	and	aqueous	buffer	(TRIS	157	
10mM,	 pH	 7.2)	 into	 separate	 chamber	 inlets	 of	 the	micromixer.	 The	 flow	 rate	158	
ratio	(FRR)	(ratio	between	solvent	and	aqueous	stream)	as	well	as	the	total	flow	159	
rate	(TFR)	of	both	streams	were	controlled	by	syringe	pumps,	calibrated	to	the	160	
syringe	inner	diameter.	FRR	varied	from	1:1	to	1:5	and	TFR	varied	from	0.5	to	6	161	
mL/min,	 extrapolated	 from	previous	 reported	methods	applying	a	 SHM	design	162	
with	a	channel	diameter	of	200	µm	(Kastner	et	al.,	2014).	The	SUV	formulation	163	
was	collected	from	the	chamber	outlet	and	dialysed	at	room	temperature	against	164	
TRIS	buffer	(10mM,	pH	7.2)	 for	removal	of	residual	solvent.	The	model	drug	of	165	
low	 aqueous	 solubility	 was	 propofol	 (2,6‐Bis(isopropyl)phenol),	 previously	166	
shown	to	correspond	to	high	encapsulation	values	 in	 liposomal	systems	due	to	167	
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its	 low	 molecular	 weight	 (Ali	 et	 al.,	 2013).	 To	 encapsulate	 propofol,	 the	 low	168	
solubility	 drug	 was	 dissolved	 with	 the	 lipids	 in	 ethanol	 (0.5	 to	 3mg/mL)	 and	169	
thereby	 liposome	 formation	 and	 encapsulation	 of	 the	 drug	 was	 performed	170	
simultaneously	using	the	micromixer	method.	171	
	172	
2.4 Lipid film hydration and sonication 173	
Multilamellar	 vesicles	 (MLV)	 were	 prepared	 using	 the	 lipid	 film	 hydration	174	
method	 (Bangham	 et	 al.,	 1965).	 Basically,	 lipids	 were	 dissolved	 in	175	
chloroform/methanol	 (9:1	 v/v)	 and	 the	 organic	 solvent	 was	 subsequently	176	
removed	by	rotary	evaporation	under	vacuum	to	form	a	dry	lipid	film	which	was	177	
flushed	 with	 N2	 to	 ensure	 removal	 of	 solvent	 residues.	 The	 lipid	 film	 was	178	
hydrated	with	TRIS	buffer	(10	mM,	pH7.2)	to	form	MLV.	SUV	were	then	formed	179	
via	probe	sonication	(Sonirep150plus,	MSE;	5	min	at	an	amplitude	of	5).		180	
 181	
2.5 Measurement of particle characteristics  182	
Characterisation	 of	 the	 liposomes	 included	 size	 measurements	 using	 dynamic	183	
light	 scattering	 (DLS)	 (Malvern	 NanoZS),	 reported	 as	 the	 z‐average	 (intensity	184	
based	mean	 particle	 diameter)	 for	monomodal	 size	 distributions	 and	 the	 zeta	185	
potential	using	particle	electrophoresis	(Malvern	NanoZS).	Polydispersity	(PDI)	186	
measurements	(Malvern	NanoZS)	were	used	to	assess	particle	distribution.	187	
	188	
2.6 Quantification of drug concentrations 189	
Quantification	of	propofol	was	performed	by	reverse	phase	HPLC	(Luna	5µ	C18,	190	
Phenomenex,	pore	size	of	100A,	particle	size	of	5	µm).	Detector	was	UV/Vis,	at	191	
268	nm.	The	 flow	rate	was	constant	at	1.0	mL/min	throughout	with	a	gradient	192	
elution	from	5%	B	(Methanol),	95%	A	(0.1%	Trifluoroacetic	Acid	(TFA)	in	water)	193	
to	 100%	 B	 over	 10	 minutes.	 HPLC‐grade	 liquids	 were	 used,	 sonicated	 and	194	
filtered.	The	column	temperature	was	controlled	at	35ºC.	All	analysis	was	made	195	
in	Clarity,	DataApex	version	4.0.3.876.	Quantification	was	achieved	by	reference	196	
to	 a	 calibration	 curve	 produced	 from	 standards	 (six	 replicates	 in	 ethanol)	 at	197	
concentrations	from	0.01	to	1	mg/mL.	The	calibration	curve	had	a	linearity	R2	≥	198	
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0.997,	 and	 all	 measurements	 were	 within	 the	 level	 of	 detection	 and	 level	 of	199	
quantification.	200	
	201	
2.7 Determination of drug loading into liposomes 202	
The	amount	of	drug	 loaded	 into	 the	bilayer	was	measured	by	determination	of	203	
the	 residual	 amount	 of	 drug	 in	 the	 liposome	 bilayer	 after	 removal	 of	 non‐204	
entrapped	drug	by	dialysis	(sink	conditions)	against	1	L	of	TRIS	buffer,	10mM	pH	205	
7.2	 (3500	 Da,	 Medicell	 Membranes	 Ltd.,	 London,	 UK).	 The	 drug	 content	 was	206	
measured	by	HPLC	as	described	 in	 section	2.6.	 This	protocol	was	 validated	by	207	
assessing	the	rate	of	propofol	removal	by	dialysis.		208	
 209	
2.8 Stability study 210	
For	the	stability	study,	formulations	of	propofol‐loaded	SUV	were	stored	at	4°C,	211	
25°C	 and	 40°C	 in	 pharmaceutical	 grade	 stability	 cabinets	 over	 60	 days	 (time	212	
point	measurements	at	day	0,	7,	14,	21,	28	and	60).	Samples	were	taken	at	these	213	
specific	time	points	for	measurement	of	particle	characteristics	(section	2.5)	and	214	
drug	 loading	 (section	 2.6).	 Samples	were	 dialysed	 against	 500	mL	TRIS	 buffer	215	
(10	mM,	 pH7.2,	 sink	 conditions)	 at	 each	 time	 point	 to	 remove	 non‐entrapped	216	
propofol.	Propofol	content	remaining	in	the	liposome	formulation	was	assessed	217	
by	HPLC	as	described	in	section	2.6.	218	
	219	
2.9 Recovery of lipids and propofol   220	
To	assess	the	overall	lipid	and	propofol	recovery	in	the	microfluidics	method,	the	221	
amount	 of	 lipid	 and	 propofol	 was	 measured	 by	 HPLC	 and	 expressed	 as	 %	222	
recovery	 compared	 to	 the	 initial	 amount	 of	 lipids	 or	 propofol	 available	 in	 the	223	
stock.	The	HPLC	method	was	the	same	as	described	section	2.6,	and	lipids	were	224	
quantified	by	an	evaporative	 light	scattering	(ELS)	detector	(Sedere,	Sedex	90),	225	
set	at	52°C	and	coupled	to	the	HPLC.		226	
	227	
2.10 Freeze Fracturing Imaging 228	
Two	microlitres	of	 liposome	suspension	were	placed	in	a	ridged	gold	specimen	229	
support	 and	 frozen	 rapidly	 by	 plunging	 into	 a	 briskly	 stirred	 mixture	 of	230	
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propane:isopentane	(4:1)	cooled	in	a	liquid	nitrogen	bath.	Fracturing,	with	a	cold	231	
knife,	 and	 replication	were	performed	 in	a	Balzers	BAF	400D	apparatus	under	232	
conditions	similar	to	those	described	previously	for	freeze‐fracture	of	liposomes	233	
(Forge	et	al.,	1978;	Forge	et	al.,	1989).	The	replicas	generated	were	floated	off	on	234	
water,	cleaned	in	domestic	bleach	diluted	1:1	in	distilled	water,	and	then	washed	235	
several	 times	 in	 distilled	 water	 before	 mounting	 on	 grids	 for	 electron	236	
microscopy.	The	replicas	were	viewed	in	a	JEOL	1200EXII	transmission	electron	237	
microscope	operating	at	80kv	and	digital	images	collected	with	a	Gatan	camera.	238	
Images	of	the	freeze‐fractured	samples	are	presented	in	reverse	contrast	so	that	239	
shadows	appear	black.	Fracturing	imaging	was	performed	by	Prof.	Andrew	Forge	240	
at	UCL	Ear	Institute,	London,	UK.		241	
	242	
2.11 Drug release study 243	
The	 in‐vitro	 release	 rate	 of	 the	 drug	 was	 determined	 by	 incubating	 the	 drug‐244	
loaded	 liposomes	 in	1	L	TRIS	buffer	 (10mM,	pH	7.2)	after	 removal	of	 the	non‐245	
incorporated	 drug,	 at	 37°C	 in	 a	 shaking	 water	 bath	 (150	 shakes/min).	 Three	246	
independent	 formulations	 of	 drug‐loaded	 liposomes	made	by	 the	microfluidics	247	
method	(TFR	2	mL/min,	FRR	1:3)	and	standard	lipid	film	hydration	followed	by	248	
sonication	were	incubated	(3	mL	per	formulation)	and	samples	of	200	µL	were	249	
withdrawn	 at	 time	 intervals	 of	 0.5	 h,	 1	 h,	 2	 h,	 4	 h,	 8	 h	 and	 16	 h.	 Drug	250	
quantification	was	 performed	 as	 described	 in	 section	 2.6	 and	 expressed	 as	%	251	
cumulative	release	relative	to	the	initial	amount	of	drug	encapsulated.	252	
	253	
2.12 Incorporation of an aqueous marker within liposomes 254	
To	validate	the	formulation	of	liposomes,	the	presence	of	an	aqueous	core	within	255	
the	 nanoparticles	 manufactured	 was	 verified	 by	 including	 and	 imaging	 of	 an	256	
aqueous	fluorescent	dye.	Liposomes	were	manufactured	as	described	in	section	257	
2.3	and	2.4	with	1	mM	Carboxyfluorescein	(CF)	 included	 in	 the	aqueous	buffer	258	
(TRIS,	10	mM,	pH	7.2).	Liposomes	with	entrapped	CF	were	separated	from	un‐259	
entrapped	 dye	 by	 dialysis	 over	 night	 against	 1	 L	 fresh	 TRIS	 buffer,	 pH	 7.2.	260	
Liposomes	 were	 imaged	 under	 a	 confocal	 microscope	 SP5	 TCS	 II	 MP,	 Leica	261	
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Microsystems,	 Leica	 TCSSP5	 II,	 63x	 objective	 (HCX	 PLAPO	 63x/1.4‐0.6	 oil	 CS).	262	
Images	were	taken	by	Charlotte	Bland,	Aston	University,	ARCHA	facility.	263	
 264	
2.13 Statistical tools 265	
If	not	stated	otherwise,	results	were	reported	as	mean	±	standard	deviation	(SD).	266	
One‐	 or	 two‐way	 analysis	 of	 variance	 (ANOVA)	 was	 used	 to	 assess	 statistical	267	
significance,	 followed	 by	 Tukeys	 multiple	 comparing	 test	 and	 t‐test	 was	268	
performed	for	paired	comparisons.	Significance	was	acknowledged	for	p	values	269	
less	 than	0.05	 (marked	with	 *).	All	 calculations	were	made	 in	GraphPad	Prism	270	
version	6.0	(GraphPad	Software	Inc.,	La	Jolla,	CA).	271	
	272	
3 Results and discussion 273	
3.1 Influence  of  the  flow  rate  ratio  of  aqueous  and  solvent  stream  on 274	
liposome size 275	
The	 increase	 in	polarity	 throughout	 the	chamber	drives	 the	 formation	of	 small	276	
unilamellar	 liposomes	(SUV)	 in	milliseconds	of	mixing.	For	 their	 formation,	 the	277	
rate	 of	 mixing	 as	 well	 as	 the	 ratio	 of	 aqueous	 to	 solvent	 stream	 has	 been	278	
anticipated	 as	 crucial	 factors.	 The	 formation	 of	 the	 liposomes	 is	 based	 on	 a	279	
nanoprecipitation	reaction,	where	supersaturation	occurs	and	the	liposomes	are	280	
formed	by	self‐assembly	after	aggregation	of	the	lipid	molecules.	The	initial	aim	281	
of	this	work	was	to	assess	the	formation	of	liposomes	by	microfluidic	mixing	and	282	
assess	 the	 efficacy	 of	 this	 system	 to	 act	 as	 a	 solubilising	 agent.	 Therefore,	283	
liposomes	were	prepared	from	PC	and	Cholesterol	(16:4	molar	ratio,	8:1	w/w)	at	284	
different	 total	 flow	 rates	 (TFR)	 and	 flow	 rate	 ratios	 (FRR)	 and	 the	 size,	285	
polydispersity	and	zeta	potential	were	measured.		286	
	287	
Liposomes	formed	at	low	flow	rate	ratio	(1:1)	showed	the	largest	size	of	around	288	
450	nm;	increasing	the	flow	rate	ratio	resulted	in	smaller	liposomes	(around	40	‐	289	
50	nm)	at	 constant	 flow	 rates	of	2	mL/min	 (TRIS,	10	mM,	pH7.2)	 (Figure	2A).		290	
However,	increasing	the	flow	rate	ratio	increased	polydispersity	(to	a	maximum	291	
of	0.4;	Figure	2B).	Liposomes	prepared	at	a	 flow	rate	ratio	of	1:3	are	shown	 in	292	
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Figure	2C,	demonstrating	their	small	nature,	with	average	sizes	of	the	vesicles	in	293	
agreement	 with	 average	 vesicle	 diameters	 obtained	 by	 particle	 sizing	 via	294	
dynamic	 light	 scattering	 (~40	 nm).	 In	 contrast,	 the	 smallest	 vesicle	 size	 of	 a	295	
comparable	 formulation	 achievable	 via	 probe	 sonication	 with	 this	 lipid	296	
formulation	was	100	nm	 in	 size	 at	PDIs	of	0.3	 (data	not	 shown).	To	verify	 the	297	
formation	 of	 liposomes,	 rather	 than	 micelles,	 the	 liposomes	 made	 by	 the	298	
microfluidics	method	were	prepared	encapsulating	an	aqueous	fluorescent	dye,	299	
carboxyfluorescein	(CF,	1	mM),	which	was	included	in	the	aqueous	phase	during	300	
liposome	manufacturing	by	microfluidics	and	lipid	film	hydration.	After	removal	301	
of	the	free	CF	by	dialysis	overnight,	the	remaining	dye	entrapped	in	the	particles	302	
was	visualized	by	confocal	microscopy.	Bright	green	fluorescent	cores	visible	in	303	
the	particles	manufactured	by	the	microfluidics	method	(Figure	2D)	were	in	line	304	
with	images	obtained	from	liposomes	manufactured	with	the	lipid	film	hydration	305	
method	(images	not	shown);	which	confirms	the	presence	of	aqueous	cores	and	306	
the	formation	of	liposomes	in	the	novel	microfluidics	method.	307	
	308	
	
	
	 	
12	
	
Figure	2:	 Liposome	 size	 (A)	 and	polydispersity	 (B)	of	 vesicles	 formulated	with	309	
microfluidics	method	 at	 increasing	 flow	 ratios.	 ns	 =	 not	 significant	 (p>0.05),	 *	310	
denotes	 statistical	 significance	 (p<0.05)	 in	 comparison	 to	 FRR	 1:1	 	 (C)	 Freeze	311	
fracturing	electron	microscopy	 images	for	empty	 liposomes	manufactured	with	312	
the	microfluidics	method.	 Bar	 represents	 100	 nm.	 (D)	 Fluorescent	microscope	313	
images	 of	 liposomes	 manufactured	 with	 the	 microfluidics	 method,	314	
carboxyfluorescein	was	encapsulated	within	the	aqueous	core	of	the	vesicles	as	a	315	
control	for	the	manufacturing	of	bilayer	liposomes.	Bar	represents	20	µm.			316	
	317	
	318	
	319	
These	 impact	of	 flow	 rate	 ratio	on	vesicle	 size	 are	 in	agreement	with	previous	320	
work	 showing	 that	 the	 increase	 in	 FRR	 reduces	 the	 resulting	 size	 of	 the	321	
liposomes	 (Jahn	et	 al.,	 2010;	Kastner	et	 al.,	 2014;	Zook	and	Vreeland,	2010).	A	322	
correlation	between	higher	 flow	rate	 ratios	and	smaller	 liposome	particles	has	323	
been	 reported	 using	 liposomes	 composed	 of	 1‐palmitoyl,	 2‐oleoyl	324	
phosphatidylcholine	 (POPC),	 cholesterol	 and	 the	 triglyceride	 triolein,	 which	325	
resulted	 in	 the	 production	 of	 vesicular	 structures	with	 sizes	 ranging	 from	140	326	
nm	to	40	nm	dependent	on	the	FRR	chosen	and	triglyceride	emulsions	between	327	
20−	50	nm	size	with	nonpolar	cores	(Zhigaltsev	et	al.,	2012).	The	overall	 lower	328	
amount	 of	 residual	 solvent	 present	 at	 higher	 FRR	 employed	 decreases	 the	329	
particle	 fusion	 (Ostwald	 ripening),	 which	 leads	 to	 the	 formation	 of	 smaller	330	
particles	(Zhigaltsev	et	al.,	2012).	The	increase	in	polydispersity	may	be	a	result	331	
of	increased	dilution	at	higher	FRR	reducing	the	rate	of	diffusional	mixing	within	332	
the	micromixer	as	noted	in	previous	studies	applying	a	SHM	mixer	for	liposome	333	
manufacturing	 (Kastner	 et	 al.,	 2014).	With	 diffusion	 being	 proportional	 to	 the	334	
lipid	 concentration,	 increasing	 FRR	 is	 effectively	 reducing	 the	 lipid	335	
concentration,	 thus	 reducing	 the	 rate	 of	 diffusion,	 leading	 to	partly	 incomplete	336	
nucleation	 and	 a	 lower	 rate	 of	 liposome	 formation	 inside	 the	 micromixer	337	
(Balbino	et	al.,	2013b).	Overall,	 these	findings	demonstrate	that	a	FRR	of	1:2	to	338	
1:4	result	in	liposomes	of	the	smallest	size	and	polydispersity.	The	dilution	factor	339	
(due	 to	 flow	 ratios	 chosen	 involved	 in	 the	 SHM	 method)	 is	 overall	 lower	340	
compared	to	ratios	employed	in	the	flow‐focusing	method,	which	can	reach	up	to	341	
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60	(Jahn	et	al.,	2010;	Jahn	et	al.,	2007;	Jahn	et	al.,	2004).	Furthermore,	the	SHM	342	
method	 enhances	 the	 diffusional	mixing	 due	 to	 the	 herringbone	 structures	 on	343	
the	 channel	 wall	 (Stroock	 et	 al.,	 2002),	 which	 results	 in	 an	 enhanced	 mixing	344	
profiles	compared	to	the	flow‐focusing	technique.		345	
	346	
3.2 Influence of flow rate on throughput and particle characteristics 347	
To	assess	the	ability	of	the	system	as	a	potential	high‐throughput	manufacturing	348	
method	for	liposomal	solubilisation	systems,	we	increased	the	total	flow	rate	3‐349	
fold	whilst	maintaining	the	ratio	between	aqueous	and	solvent	stream	constant.	350	
Liposome	 size	was	 shown	 to	 be	 independent	 of	 the	 applied	 flow	 rate,	with	no	351	
significant	change	in	vesicle	size	(Figure	3A),	pdi	(Figure	3B)	and	zeta	potential	352	
(‐3±2mV;	data	not	shown).	These	results	support	the	suitability	of	microfluidics	353	
manufacturing	as	a	high	throughput	method	with	liposome	characteristics	being	354	
maintained	 constant	 whilst	 increasing	 the	 total	 flow	 rate	 in	 the	 system.	 Our	355	
results	also	confirm	that	the	flow	rate	ratio	used	in	the	system	is	the	most	crucial	356	
variable	on	 liposome	size,	which	has	previously	been	demonstrated	with	other	357	
systems	(Balbino	et	al.,	2013a;	Balbino	et	al.,	2013b;	Jahn	et	al.,	2007;	Jahn	et	al.,	358	
2004;	Kastner	et	al.,	2014).	The	scalability	of	the	microfluidics	method	has	been	359	
suggested	 by	 Belliveau	 et	 al.	 2013,	 by	 parallelization	 of	 the	 mixer	 chamber.	360	
Scalability	 and	 increase	 in	 throughput	 together	 demonstrate	 the	 industrial	361	
applicability	comparable	with	scale‐up	options	available	(Wagner	and	Vorauer‐362	
Uhl,	2011).	363	
	364	
	365	
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Figure	3:	 Liposome	 size	 (A)	 and	polydispersity	 (B)	of	 vesicles	 formulated	with	366	
microfluidics	at	 increasing	flow	rates	and	constant	flow	ratio	of	1:3,	n	=	3,	ns	=	367	
not	significant	(p>0.05).	368	
	369	
	370	
	371	
As	 shown,	 the	 increase	 in	 FRR	 is	 the	 main	 contributing	 factor	 governing	372	
liposome	size	(Figure	2A).	Nevertheless,	an	increase	in	FRR	will	 inevitably	lead	373	
to	dilution	and	lower	liposome	concentrations	in	the	final	 liposome	suspension	374	
produced.	A	subsequent	concentration	process	based	on	filtration	(Pattnaik	and	375	
Ray,	 2009),	 chromatography	 (Ruysschaert	 et	 al.,	 2005)	 or	 centrifugation	 adds	376	
additional	processing	time.	Therefore,	to	circumvent	this	additional	process	step,	377	
we	counteracted	the	dilution	of	the	lipids	at	higher	FRR	by	increasing	initial	lipid	378	
concentrations	 introduced	 to	 the	micromixer	 at	 the	 desired	 FRR.	Through	 this	379	
method,	 liposomes	 were	 manufactured	 at	 up	 to	 6	 fold	 higher	 concentrations.	380	
Increased	 lipid	 concentrations	 at	 FRR	 of	 1:3	 and	 1:5	 did	 not	 significantly	381	
(p>0.05)	 influence	 size	 and	 polydispersity	 compared	 to	 the	 standard	 lipid	382	
concentration	(Figure	4A	and	B),	whereas	at	a	FRR	of	1:1	a	significant	(p<0.05)	383	
decrease	in	vesicle	size	was	observed	(Figure	4A).	At	this	lower	FRR,	the	higher	384	
lipid	 concentrations	 may	 again	 decreasing	 particle	 fusion	 leading	 to	 the	385	
formation	of	 smaller	particles	 (Zhigaltsev	et	al.,	2012).	Nevertheless,	 this	setup	386	
allows	to	increase	the	final	liposome	concentration	according	to	the	FRR	chosen	387	
without	 adversely	 changing	 resulting	 vesicle	 size	 or	 polydispersity	 for	 the	388	
smallest	vesicle	sizes	obtained	at	higher	FRR	(Figure	4A	and	B	respectively),	due	389	
to	the	diffusional	mixing	process	in	the	SHM	design.	390	
	391	
	392	
	393	
	394	
	395	
	396	
	397	
	398	
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polydispersity	 (Figure	 5A).	 	 Particle	 size	 and	 polydispersity	 increased	 notably	419	
(ca.	 600	 nm	 and	 0.8	 respectively)	 at	 the	 highest	 propofol	 concentration	 (3	420	
mg/mL	 in	 the	 solvent	 stream,	 giving	 a	 loading	 of	 ~25mol%,	 Figure	 5A),	421	
suggesting	 the	 liposome	 system	may	have	become	 saturated	or	destabilised	 at	422	
high	propofol	concentrations	(drug‐to‐lipid	ratio	1.72	mol/mol).	 	Based	on	this,	423	
subsequent	studies	adopted	a	propofol	concentration	at	1	mg/mL	in	the	solvent	424	
stream	for	all	performed	encapsulation	studies.		425	
	426	
The	 drug	 encapsulation	 was	 further	 investigated	 as	 a	 function	 of	 FRR	 in	 the	427	
microfluidics	method.	Propofol	encapsulation	(mol%)	 in	 liposomes	prepared	at	428	
FRR	 1:1,	 1:3	 and	 1:5	 remained	 at	 approximately	 50	 mol%	 with	 no	 statistical	429	
difference.	However	this	was	significantly	higher	(p<	0.0001)	than	drug	loading	430	
in	 liposomes	 prepared	 via	 sonication	 (15	mol%;	 Figure	 5B).	 The	 drug	 loading	431	
efficiency	of	liposomes	prepared	by	sonication	is	in	line	with	previous	reported	432	
propofol	 encapsulation	 (Ali	 et	 al.,	 2013).	 Furthermore,	 drug	 encapsulation	 did	433	
not	alter	vesicle	size	or	polydispersity	(Figure	5A)	and	vesicle	sizes	obtained	by	434	
dynamic	 light	 scattering	were	verified	by	 freeze	 fracturing	 images	 (Figure	5D).	435	
This	higher	drug	loading	may	be	a	result	of	the	highly	efficient	mixing	processes	436	
occurring	during	microfluidics	that	favours	incorporation	of	propofol	within	the	437	
bilayers	 in	 the	 same	 process	 as	 the	 vesicles	 form.	 Indeed,	 the	 here	 presented	438	
method	 allows	 to	 achieve	 a	 propofol	 encapsulation	 of	 ~50	 mol%,	 which	439	
represents	 a	 total	 propofol	 amount	 of	 ~300	 mg/mL	 in	 the	 final	 liposome	440	
formulation,	 representing	 a	 2000‐fold	 increase	 to	 the	 reported	 aqueous	441	
solubility	of	propofol,	150	µg/mL	(Altomare	et	al.,	2003).		442	
	443	
	444	
	445	
	446	
	447	
	448	
	449	
	450	
	451	
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	452	
	453	
Size	
(nm)	
40	±	2	 48	±	2	 613	±	360	
PDI	 0.03	±	0.02		 0.17	 ±	
0.01		
0.8	±	0.28	
	
	
Figure	5:	(A)	Effect	of	drug	concentrations	in	the	ethanol	inlet	stream	(0.5,	1	and	454	
3	mg/mL)	on	encapsulation	efficiency	(mol%),	particle	size	and	polydispersities	455	
at	a	flow	ratio	of	1:3..	(B)	Encapsulation	efficiency	(mol%)	of	liposomes	formed	456	
with	the	microfluidics	method	at	flow	ratios	of	1:1,	1:3	and	1:5	compared	to	the	457	
encapsulation	efficiency	using	the	sonication	method.	Results	are	average	out	of	458	
triplicate	 formulations	 and	 measurements.	 ns	 =	 not	 significant	 (p>0.05),	 *	459	
denotes	 statistical	 significance	 (p<0.00001)	 in	 comparison	 to	 microfluidics‐460	
based	samples.	(C)	Recovery	of	 lipids	and	propofol	 in	the	microfluidics	method	461	
at	different	flow	ratios.	Results	are	expressed	as	%	compared	to	the	initial	lipid	462	
and	propofol	amount	present	(n	=	3).	(D)	Freeze	fracturing	electron	microscopy	463	
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images	 for	 liposomes	 loaded	 with	 the	 low	 solubility	 model	 drug	 (propofol)	464	
manufactured	with	the	microfluidics	method.	Bar	represents	100	nm	465	
	466	
	467	
	468	
To	consider,	drug	release	profiles,	the	in‐vitro	release	of	propofol	encapsulated	in	469	
liposomes	by	microfluidics	was	monitored	at	37°C	over	16	h.	Liposomes	formed	470	
with	the	microfluidics	method	had	a	significant	higher	drug	encapsulated	at	the	471	
start	 of	 the	 release	 study	 (~55	mol%)	 compared	 to	 those	 vesicles	 formed	 by	472	
sonication	(20	mol%	drug	encapsulation).	However,	relative	to	initial	loading,	an	473	
initial	release	of	ca	40%	was	observed	at	1	h	for	both	formulations,	followed	by	a	474	
continuous	 release	 of	 90%	 of	 the	 encapsulated	 drug	 was	 observed	 over	 8	 h	475	
(Figure	6).	Whereas	the	fatty	alcohol	alkyl	chain	length	was	shown	to	affect	the	476	
release	 profile	 of	 encapsulated	 propofol	 (Ali	 et	 al.,	 2013),  here	 the	 method	 of	477	
liposome	 manufacturing	 was	 shown	 to	 mainly	 affect	 the	 amount	 of	 drug	478	
incorporated	 into	 the	 liposomes,	 without	 altering	 the	 release	 profile	 of	 the	479	
encapsulated	 drug	 against	 sink	 conditions.	 Previous	 we	 have	 shown	 that	480	
solubilisation	 of	 propofol	 in	 phosphatidylcholine	 liposomes	 followed	 a	 zero‐481	
order	release	kinetics,	where	the	incorporation	of	a	higher	amount	of	cholesterol	482	
shifted	 the	 release	 rates	 towards	 a	 first‐order	 release	model	 (Ali	 et	 al.,	 2010),	483	
implying	 that	 the	 release	 kinetics	 itself	 are	 mainly	 dominated	 by	 the	 lipid	484	
composition	 and	 physicochemical	 characteristics	 rather	 than	 the	 method	 of	485	
liposome	manufacturing.	This	may	prove	advantageous	in	the	development	of	an	486	
IV	formulation;	the	pharmacokinetic	release	profile	of	propofol	has	been	studies	487	
previously	in	a	colloidal	dispersion	between	20‐100	nm	(Cai	et	al.,	2012),	where	488	
rapid	distribution	of	propofol	 compared	 to	 the	 commercial	product	Diprivan®	489	
highlighted	 the	 need	 on	 the	 development	 of	 new	 techniques	 for	 the	490	
encapsulation	of	low	solubility	drugs.		491	
	492	
	493	
	494	
	495	
	496	
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Figure	6:	 Effect	 of	manufacturing	method	 to	 the	drug	 release	of	 propofol	 from	498	
liposomes.	Results	show	the	cumulative	drug	release	profile	 from	formulations	499	
manufactured	with	 the	 standard	 lipid	 film	 hydration	 /	 sonication	method	 and	500	
microfluidics	and	represent	percentage	cumulative	release	of	initially	entrapped	501	
propofol,	expressed	as	the	means	of	three	experiments	±	SD.	502	
	503	
It	 is	 important	 to	 verify	 both	 lipid	 and	 drug	 recovery	 when	 using	 the	504	
microfluidics	 method,	 to	 ensure	 cost‐effectiveness	 and	 that	 lipid	 and	 drug	505	
concentrations	remain	locked	at	the	ratio	initially	designed	prior	to	formulation.	506	
To	date,	the	quantification	of	lipids	is	mainly	dominated	by	time	intensive	assays	507	
like	mass	 spectrometry	 (Moore	 et	 al.,	 2007).	 Here,	we	 introduce	 a	 simple	 and	508	
robust	method	of	lipid	quantification	based	on	evaporative	light	scattering	(ELS)	509	
detection	and	HPLC	separation.	We	coupled	an	ELS	detector	downstream	a	HPLC	510	
separation	method,	which	allowed	 for	quantification	of	any	solids	 in	 the	eluate	511	
with	a	lower	volatility	than	the	mobile	phase.	Microfluidics	based	liposomal‐drug	512	
formulations	 showed	 good	 recovery	 of	 the	 drug	 (88	 ‐	 92%;	 Figure	 5C),	513	
independent	of	the	FRR.	Similarly,	lipid	recovery	was	high	at	FRR	of	1:1	and	1:3	514	
(97%	and	89%;	for	FRR	1:1	and	1:3	respectively;	Figure	5C).	A	significant	drop	515	
(79%;	p<0.01)	in	lipid	recovery	was	noted	at	a	flow	ratio	of	1:5,	suggesting	that	516	
higher	 FRR	 employed	 in	 the	microfluidics	 method	may	 impede	 lipid	 recovery	517	
due	to	enhanced	dilution	in	the	chamber.	Nevertheless,	the	smallest	vesicle	size	518	
(~50nm)	can	be	obtained	at	a	FRR	of	1:3	(Figure	2A)	and	any	further	increase	in	519	
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FRR	will	not	benefit	the	formulation	(size,	pdi	and	drug	encapsulation).	Based	on	520	
this,	we	chose	the	FRR	1:3	for	a	long‐term	stability	study.	521	
	522	
3.4 The  effect of manufacturing methods on  liposome  stability  and drug 523	
encapsulation over 8 weeks  524	
The	SHM	method	was	previously	 investigated	 for	 the	encapsulation	of	a	highly	525	
soluble	drug,	with	approximately	100%	loading	efficiencies	being	reported	using	526	
doxorubicin	as	a	model	drug	(Zhigaltsev	et	al.,	2012);	the	authors	demonstrated	527	
high	drug	retention	of	encapsulated	drug	with	liposomes	stored	at	4°C	over	the	528	
course	of	 eight	weeks	 (Zhigaltsev	et	 al.,	 2012).	 	 Following	 the	 assessment	 that	529	
liposomes	manufactured	 by	 the	microfluidics	 method	 yields	 significant	 higher	530	
encapsulation	of	propofol,	similarly	we	performed	an	eight‐week	stability	study	531	
to	verify	the	integrity	of	the	vesicles	at	different	storage	temperatures.	Vesicles	532	
were	prepared	using	microfluidics	as	described	above,	and	the	initial	amount	of	533	
propofol	 encapsulated	 was	 determined	 after	 removal	 of	 free	 drug	 by	 dialysis.	534	
Vesicles	 were	 stored	 at	 4°C,	 25°C/60%RH	 and	 40°C/75%RH	 (standard	 ICH	535	
temperatures)	 in	 pharmaceutical	 grade	 stability	 cabinets	 and	 the	 formulations	536	
made	by	the	sonication	method	were	stored	at	25°C/60%RH	(Figure	7,	Table	1),	537	
acting	 as	 the	 control	 method.	 The	 control	 liposomes	 formed	 by	 sonication	538	
showed	 good	 stability	 in	 terms	 of	 size	 retention	 over	 the	 course	 of	 the	 study.	539	
Similarly,	 for	 liposomes	 prepared	 using	 microfluidics,	 vesicle	 size	 remained		540	
unaffected	 after	 storage	 over	 8	weeks	 at	 4°C	 and	 25°C.	 In	 contrast,	 liposomes	541	
stored	 at	 40°C	 significantly	 increase	 in	 size	 from	 initially	 55	 nm	 to	 120	 nm	542	
(Figure	 7A),	 with	 no	 notable	 affect	 to	 polydispersity,	 suggesting	 the	 liposome	543	
population	as	a	whole	has	changed	 in	size	rather	 than	a	sub‐set	of	 the	vesicles	544	
(Table	1).			545	
	546	
	547	
Table	1:	Polydispersity	 at	different	 storage	 conditions	 for	8	weeks.	Results	 are	548	
mean	out	of	triplicate	formulations	and	measurements.	549	
Day	 0	 7	 14 21 28 60	
Microfluidics	 	 	 	
4°C		 0.403	±	0.02	 0.286	±	0.01 0.282	±	0.01	 0.295	±	0.01 0.261	±	0.01	 0.	305	±	0.01
21	
	
25°C		 0.403	±	0.02	 0.295	±	0.01 0.279	±	0.01 0.301	±	0.04 0.302	±	0.03	 0.266	±	0.03
40°C	 0.403	± 0.02	 0.254	±	0.001 0.121	±	0.02 0.119	±	0.001 0.129	±	0.01	 0.221	±	0.01
Sonication	 	 	 	
25°C		 0.656	±	0.02	 0.652	±	0.02 0.522	±	0.15 0.658	±	0.049 0.552	±	0.04	 0.505	±	0.06
	550	
Figure	 7:	 Size	 (A)	 and	 drug	 encapsulation	 (mol%)	 (B)	 at	 different	 storage	551	
conditions	 over	 8	 weeks.	 Results	 are	 mean	 of	 triplicate	 formulations	 and	552	
measurements.	553	
	554	
Minor	 (but	 not	 significant)	 drug	 loss	 from	 the	 liposomes	was	 detected	 for	 the	555	
formulations	at	4°C	and	25°C	after	 the	 first	7	days	of	storage	(Figure	7B),	after	556	
which	the	formulations	remained	stable	with	final	drug	encapsulation	values	of	557	
41±1	 mol%	 and	 41±4	 mol%	 at	 4°C	 and	 25°C	 storage	 conditions	 respectively	558	
(Figure	7B).		Similarly,	with	liposomes	formulated	using	sonication	showed	and	559	
initial	drug	loss	when	stored	at	25°C/60%RH	which	then	plateaued	out	(Figure	560	
7B).	 	Notable	drug	loss	from	the	microfluidic	systems	was	only	seen	when	they	561	
were	 stored	 at	 elevated	 temperatures	 with	 the	 formulation	 stored	 at	 40°C	562	
showing	almost	 complete	drug	 loss	over	 the	 course	of	 the	 stability	 study,	with	563	
only	5±1	mol%	drug	remaining	encapsulated	after	8	weeks,	similar	 to	 the	 final	564	
drug	 encapsulated	 in	 the	 sonicated	 liposomes	 which	 were	 stored	 at	565	
25°C/60%RH	 (Figure	 7B).	 Overall,	 vesicles	 produced	 with	 the	 microfluidics	566	
method	were	 smaller	with	 a	 lower	polydispersity	 than	 those	obtained	by	 lipid	567	
film	hydration	/	sonication.	The	vesicles	manufactured	by	sonication	maintained	568	
their	size	around	100±20	nm	throughout	the	stability	study	(stored	at	25°C)	as	569	
well	 as	 their	 polydispersity	 (Table	 1).	 Results	 suggest	 that	 the	 method	 of	570	
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manufacturing	mainly	 impacts	 the	drug	encapsulation	 rather	 than	 the	physical	571	
properties	(size,	pdi,	zeta	potential).	Stability	of	 the	 formulations	 is	crucial	and	572	
these	 results	 demonstrate	 that	 liposomes	 formed	 by	 the	microfluidics	method	573	
remain	over	two	months	at	conditions	of	4	and	25°C.	574	
	575	
3.5 Conclusion 576	
Here,	for	the	first	time,	we	have	demonstrated	a	high‐throughput,	robust	method	577	
of	preparing	size‐controlled	liposomes	as	solubilising	agents	using	microfluidics.	578	
These	 liposomes	 have	 well	 defined,	 scalable,	 process	 controlled,	 physico‐579	
chemical	 attributes	 demonstrating	 this	 method	 is	 suitable	 for	 pre‐clinical	 and	580	
clinical	production	of	liposomes.	Drug	loading	was	shown	to	be	in	an	applicable	581	
range	 for	 clinical	 application	 (Biebuyck	 et	 al.,	 1994).	 Furthermore,	 using	 this	582	
novel	method,	liposome	manufacturing	and	drug	encapsulation	are	processed	in	583	
a	 single	 process	 step,	 circumventing	 an	 additional	 drug	 loading	 step	584	
downstream,	 which	 notably	 reduces	 the	 time	 for	 production	 of	 stable	 drug‐585	
loaded	vesicles	of	specified	physico‐chemical	characteristics.		586	
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